REFERENCES
1. Datta J, Palmer MJ, Tanton C, et al. Prevalence of infertility and help seeking among 15 000 women and men. Hum Reprod. 2016;31:2108-18.
2. Zhou Z, Zheng D, Wu H, et al. Epidemiology of infertility in China: a population-based study. BJOG. 2018;125:432-41.
3. Zhang X, Zhang M, Zhao Z, et al. Geographic variation in prevalence of adult obesity in china: results from the 2013-2014 national chronic disease and risk factor surveillance. Ann Intern Med. 2020;172:291-3.
4. Barbouni K, Jotautis V, Metallinou D, et al. When weight matters: how obesity impacts reproductive health and pregnancy - a systematic review. Curr Obes Rep. 2025;14:37.
5. Johnson AP, Vu TT, Simon J, Ryan GL. Special considerations in assisted reproductive technology for patients with obesity. Fertil Steril. 2025;124:212-8.
7. Wu M, Huang Y, Zhu Q, et al. Adipose tissue and ovarian aging: potential mechanism and protective strategies. Ageing Res Rev. 2022;80:101683.
8. Rafael F, Rodrigues MD, Bellver J, et al. The combined effect of BMI and age on ART outcomes. Hum Reprod. 2023;38:886-94.
9. Wang RQ, Deng ZM, Chen GT, Dai FF, Xia LB. Obesity and recurrent spontaneous abortion: the crucial role of weight management in pregnancy. Reprod Biol Endocrinol. 2025;23:10.
10. Cozzolino M, García-Velasco JA, Meseguer M, Pellicer A, Bellver J. Female obesity increases the risk of miscarriage of euploid embryos. Fertil Steril. 2021;115:1495-502.
11. Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27:584-618.
12. Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687-708.
13. Tay CT, Loxton D, Bahri Khomami M, Teede H, Harrison CL, Joham AE. High prevalence of medical conditions and unhealthy lifestyle behaviours in women with PCOS during preconception: findings from the Australian Longitudinal Study on Women’s Health. Hum Reprod. 2023;38:2267-76.
14. Zhang Y, Chen ZJ, Zhao H. Polycystic ovary syndrome: a metabolic disorder with therapeutic opportunities. Cell Metab. 2025;37:1932-49.
15. Experts Consensus Group on the Body Quality Management Approach and Process for Overweight/Obese Infertility Patients. Expert consensus on the weight management of overweight/obese infertility patients in China. Chin J Reprod Contracept. 2020;40:965-71. (in Chinese).
16. Ruiz-González D, Cavero-Redondo I, Hernández-Martínez A, et al. Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Hum Reprod Update. 2024;30:472-87.
17. Saadati S, Mason T, Godini R, Vanky E, Teede H, Mousa A. Metformin use in women with polycystic ovary syndrome (PCOS): opportunities, benefits, and clinical challenges. Diabetes Obes Metab. 2025;27 Suppl 3:31-47.
18. Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12:CD013505.
19. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843-52.
20. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873-88.
21. Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovasc Res. 2024;119:2825-42.
22. Wilding JPH, Calanna S, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. Reply. N Engl J Med. 2021;385:e4.
23. Garvey WT, Batterham RL, Bhatta M, et al.; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-91.
24. Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025;90:103680.
25. Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine. 2024;69:102475.
26. Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25:504-17.
27. Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179:1-11.
28. Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol. 2017;87:767-74.
29. Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35:121-7.
30. Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14:1081-9.
31. Darıcı E, Pais F, Leemans L, et al. From body mass index to body composition in female infertility. Reprod Biomed Online. 2025;51:104941.
32. Ling J, Wang T, Huang W, et al. Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Obes Metab. 2025;27:6139-53.
33. Wen Q, Fang S, Liang Y, et al. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Front Endocrinol. 2023;14:1156521.
34. Huang R, He Y. The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis. BMC Womens Health. 2025;25:282.
35. Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol. 2022;13:945609.
36. Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023;12:5921.
37. Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an association exist between menstrual cycle length within the normal range and ovarian reserve biomarkers during the reproductive years? Hum Reprod Update. 2020;26:904-28.
38. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21.
39. Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. Hormones. 2017;16:373-80.
40. Roberts R, Markande A, Kasaven L, et al. Obesity and female reproductive health; is there a role for glucagon-like peptide-1 receptor agonists? Obes Rev. 2026;27:e70015.
41. Bednarz K, Kowalczyk K, Cwynar M, et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022:23.
42. Guo S, Li X, Liu M, et al. Semaglutide alleviates ovarian oxidative stress and autophagy via the PI3K/AKT/mTOR pathway in mice with polycystic ovary syndrome. Drug Des Devel Ther. 2025;19:4297-310.
43. Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017;17:5.
44. Wang Y, Ni Z, Li K. The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2021;37:1072-8.
45. Greenwood EA, Pasch LA, Cedars MI, Legro RS, Eisenberg E, Huddleston HG; Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network. Insulin resistance is associated with depression risk in polycystic ovary syndrome. Fertil Steril. 2018;110:27-34.
